clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-11-521-524clinmed-648Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESИнгибитор фибринолиза, активируемый тромбином, и его клиническое значениеTAFI phenomenon and its clinical significancehttps://orcid.org/0000-0001-5331-2655БокаревИ. Н.BokarevI. N.

Бокарев Игорь Николаевич — д-р мед. наук, профессор, президент Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудистой стенки им. А.А. Шмидта–Б.А. Кудряшова

129327, Москва

Bokarev Igor N.

129327, Moscow

https://orcid.org/0000-0002-7426-9040МельниковА. П.MelnikovA. P.

Мельников Андрей Павлович — канд. мед. наук, старший научный сотрудник МОНИИАГ 

МОНИИАГ,101000, Москва

Всероссийская ассоциация  им. А.А. Шмидта–Б.А. Кудряшова, 129327, Москва

Melnikov Andrey P. 

101000, Moscow

129327, Moscow

https://orcid.org/0000-0002-1582-8455БурыхС. И.BurykhS. I.

Бурых София Игоревна — клинический ординатор кафедры акушерства и гинекологии 

101000, Москва

Burykh Sofia I.

 101000, Moscow

sburyh@gmail.comВсероссийская ассоциация по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта–Б.А. КудряшоваРоссияRussian Association on Thrombosis, Hemostasis and Vascular Pathology A. Schmidt–B. KudryashovRussian FederationГБУЗ МО «Московский областной НИИ акушерства и гинекологии»; Всероссийская ассоциация по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта–Б.А. КудряшоваРоссияMoscow Regional Research Institute of Obstetrics and Gynecology; Russian Association on Thrombosis, Hemostasis and Vascular Pathology A. Schmidt–B. KudryashovRussian FederationГБУЗ МО «Московский областной НИИ акушерства и гинекологии»РоссияMoscow Regional Research Institute of Obstetrics and GynecologyRussian Federation20231212202310111521524Copyright © Бокарев И.Н., Мельников А.П., Бурых С.И., 20232023Бокарев И.Н., Мельников А.П., Бурых С.И.Bokarev I.N., Melnikov A.P., Burykh S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/648

Ингибитор фибринолиза, активируемый тромбином (thrombin activatable fi brinolysis inhibitor — TAFI), является одним из ключевых белков систем фибринолиза и воспаления. На основании данных литературы представлены сведения о биологических эффектах TAFI, механизмах его активации, полиморфизме генов, определяющем длительность его действий и активность. Перечислены нозологические формы, где TAFI имеет значение в патогенезе развития болезней, его роль при экспериментальных и лабораторных исследованиях, возможности фармакологического влияния на активность этого белка.

Thrombin activatable fi brinolysis inhibitor (TAFI) is one of the key proteins of fi brinolysis and infl ammation systems. Based on  literature data, information is presented on the biological eff ects of TAFI, the mechanisms of its activation, gene polymorphism  that determines the duration of its action and activity. Nosological forms are listed, where TAFI is important in the pathogenesis  of the development of diseases, its role in experimental and laboratory studies, and the possibility of pharmacological infl uence  on the activity of this protein.

ингибитор фибринолизаактивированный тромбиномгемокоагуляцияфибринолизвоспалениеосложнение беременностиthrombin-activated fibrinolysis inhibitorhemocoagulationfibrinolysisinflammationpregnancy complicationReferencesБокарев И.Н., Попова Л.В., Савин А.А. ДВС-синдром и постоянное внутрисосудистое микросвертывание крови. Москва. 2016.Bokarev I.N., Popova L.V., Savin A.A. DIC-syndrom and Constant Intravascular Microcoagulation of blood. Moscow. 2016. (In Russian).Федоренко В.А., Мельников А.П. Нарушения фибринолиза в акушерско-гинекологической практике. Российский вестник акушера-гинеколога. 2022;22(6):18–26. DOI: 10.17116/rosakush20222206118Fedorenko V.A., Melnikov A.P. Fibrinolysis disorders in obstetric and gynecological practice. Russian Bulletin of an obstetrician-gynecologist.2022;22(6):18–26. (In Russian). DOI: 10.17116/rosakush20222206118Nesheim M., Bajzar L. The discovery of TAFI. J. Thromb. Haemostasis. 2005;3(10):2139–2146. DOI: 10.1111/j.1538-7836.2005.01280.xNesheim M., Bajzar L. The discovery of TAFI. J. Thromb. Haemostasis. 2005;3(10):2139–2146. DOI: 10.1111/j.1538-7836.2005.01280.xKwaan H.C. The role of fi brinolytic system in health and disease. Int. J. Mol. Sci. 2022;23(9):5262. DOI: 10.3390/ijms23095262Kwaan H.C. The role of fi brinolytic system in health and disease. Int. J. Mol. Sci. 2022;23(9):5262. DOI: 10.3390/ijms23095262Urano T., Castellino F.J., Suzuki Y. Regulation of plasminogen activation on cell surfaces and fi brin. J. Thromb. Haemost. 2018;16(8):1487–1497. DOI:10.1111/jth.14157Urano T., Castellino F.J., Suzuki Y. Regulation of plasminogen activation on cell surfaces and fi brin. J. Thromb. Haemost. 2018;16(8):1487–1497. DOI:10.1111/jth.14157Marta-Enguita J., Navarro-Oviedo M., Muñoz R. et al. Inside the thrombus: association of hemostatic parameters with outcomes in large vessel stroke patients. Front. Neurol. 2021;12:599498. DOI:10.3389/fneur.2021.599498Marta-Enguita J., Navarro-Oviedo M., Muñoz R. et al. Inside the thrombus: association of hemostatic parameters with outcomes in large vessel stroke patients. Front. Neurol. 2021;12:599498. DOI:10.3389/fneur.2021.599498Bridge K., Revill C., Macrae F. et al. Inhibition of plasmin-mediated TAFI activation may aff ect development but not progression of abdominal aortic aneurysms. PLoS One. 2017;12(5):e0177117. DOI: 10.1371/journal.pone.0177117Bridge K., Revill C., Macrae F. et al. Inhibition of plasmin-mediated TAFI activation may aff ect development but not progression of abdominal aortic aneurysms. PLoS One. 2017;12(5):e0177117. DOI: 10.1371/journal.pone.0177117Okada M., Tominaga N., Honda G., Nishioka J., Akita N., Hayashi T., Suzuki K., Moriuchi H. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation. Blood Adv. 2020;4(12):2631–2639. DOI: 10.1182/bloodadvances.2019001155Okada M., Tominaga N., Honda G., Nishioka J., Akita N., Hayashi T., Suzuki K., Moriuchi H. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation. Blood Adv. 2020;4(12):2631–2639. DOI: 10.1182/bloodadvances.2019001155Wyseure T., Cooke E.J., Declerck P.J. et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood. 2018;132(15):1593–1603. DOI: 10.1182/blood-2018-01-8284349001155Wyseure T., Cooke E.J., Declerck P.J. et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood. 2018;132(15):1593–1603. DOI: 10.1182/blood-2018-01-8284349001155Colucci M., Incampo F., Cannavò A. et al. Reduced fi brinolytic resistance in patients with factor XI defi ciency. Evidence of a thrombinindependent impairment of the thrombin-activatable fi brinolysis inhibitor pathway. J. Thromb. Haemost. 2016;14(8):1603–1614. DOI: 10.1111/jth.13342Colucci M., Incampo F., Cannavò A. et al. Reduced fi brinolytic resistance in patients with factor XI defi ciency. Evidence of a thrombinindependent impairment of the thrombin-activatable fi brinolysis inhibitor pathway. J. Thromb. Haemost. 2016;14(8):1603–1614. DOI: 10.1111/jth.13342Totoki T., Ito T., Kakuuchi M., Yashima N., Maruyama I., Kakihana Y. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature. Thromb. J. 2022;20(1):6.Totoki T., Ito T., Kakuuchi M., Yashima N., Maruyama I., Kakihana Y. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature. Thromb. J. 2022;20(1):6.Vollrath J.T., Marzi I., Herminghaus A., Lustenberger T., Relja B. Post-traumatic sepsis is associated with increased c5a and decreased TAFI levels. J. Clin. Med. 2020;9(4)1230. DOI: 10.3390/jcm9041230Vollrath J.T., Marzi I., Herminghaus A., Lustenberger T., Relja B. Post-traumatic sepsis is associated with increased c5a and decreased TAFI levels. J. Clin. Med. 2020;9(4)1230. DOI: 10.3390/jcm9041230Bazzi Z.A., Lanoue D., El-Youssef M. et al. Activated thrombinactivatable fi brinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer. 2016;16:328. DOI: 10.1186/s12885-016-2359-1Bazzi Z.A., Lanoue D., El-Youssef M. et al. Activated thrombinactivatable fi brinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer. 2016;16:328. DOI: 10.1186/s12885-016-2359-1Radovanović-Dinić B., Tešić-Rajković S., Ignjatovic A., Grgov S. Thrombin activatable fi brinolysis inhibitor as an indicator of the severity of acute pancreatitis. Turkish J. Gastroenterol. 2018;29(4):488–493: DOI: 10.5152/tjg.2018.17666Radovanović-Dinić B., Tešić-Rajković S., Ignjatovic A., Grgov S. Thrombin activatable fi brinolysis inhibitor as an indicator of the severity of acute pancreatitis. Turkish J. Gastroenterol. 2018;29(4):488–493: DOI: 10.5152/tjg.2018.17666Gumus I.I., Kargili A., Karakurt F. et al. Levels of thrombin activatable fi brinolysis inhibitor in gestational diabetes mellitus. Gynecol. Endocrinol. 2013;29(4):327–330: DOI: 10.3109/09513590.2010.501884Gumus I.I., Kargili A., Karakurt F. et al. Levels of thrombin activatable fi brinolysis inhibitor in gestational diabetes mellitus. Gynecol. Endocrinol. 2013;29(4):327–330: DOI: 10.3109/09513590.2010.501884Fang P., Cai D., Du L., Shen F., Zhang C., Li M. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion. Clin. Appl. Thromb. 2021;27. DOI: 10.1177/10760296211029720Fang P., Cai D., Du L., Shen F., Zhang C., Li M. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion. Clin. Appl. Thromb. 2021;27. DOI: 10.1177/10760296211029720Acosta-Tejeda M., Baptista-González H., Rosenfeld-Mann F., Trueba-Gómez R., García-Latorre E. Association between genotype and plasma levels of thrombin-activated fi brinolysis inhibitor (TAFI) in the development of preeclampsia. Thromb. Res. 2011;128(4):e39– 42. DOI: 10.1016/j.thromres.2011.05.019Acosta-Tejeda M., Baptista-González H., Rosenfeld-Mann F., Trueba-Gómez R., García-Latorre E. Association between genotype and plasma levels of thrombin-activated fi brinolysis inhibitor (TAFI) in the development of preeclampsia. Thromb. Res. 2011;128(4):e39– 42. DOI: 10.1016/j.thromres.2011.05.019ЕlDanasori N., Abulata N., Shaheen I.A., ElGendy A.M., ElKhayat W. Thrombin-activatable fi brinolysis inhibitor gene polymorphism (TAFI1040C/T) in women with recurrent spontaneous abortion. Clin. Appl. Thromb. 2018;24(3):532–535. DOI: 10.1177/1076029617695485ЕlDanasori N., Abulata N., Shaheen I.A., ElGendy A.M., ElKhayat W. Thrombin-activatable fi brinolysis inhibitor gene polymorphism (TAFI1040C/T) in women with recurrent spontaneous abortion. Clin. Appl. Thromb. 2018;24(3):532–535. DOI: 10.1177/1076029617695485Gorar S., Alioglu B., Ademoglu E. et al. Is there a tendency for thrombosis in gestational diabetes mellitus? J. Lab. Physicians. 2016;8(2):101–105. DOI: 10.4103/0974-2727.180790Gorar S., Alioglu B., Ademoglu E. et al. Is there a tendency for thrombosis in gestational diabetes mellitus? J. Lab. Physicians. 2016;8(2):101–105. DOI: 10.4103/0974-2727.180790Godtfredsen A.C.M., Sidelmann J.J., Gram J.B., Andersen M., GlintborgD. Fibrin lysability is associated with central obesity and infl ammation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 2020;99(8):1078–1084. DOI: 10.1111/aogs.13825Godtfredsen A.C.M., Sidelmann J.J., Gram J.B., Andersen M., GlintborgD. Fibrin lysability is associated with central obesity and infl ammation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 2020;99(8):1078–1084. DOI: 10.1111/aogs.13825Karakurt F., Gumus II., Bavbek N. et al. Increased thrombin-activatable fi brinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol. Endocrinol. 2008;24(9):491– 497. DOI: 10.1080/09513590802291824Karakurt F., Gumus II., Bavbek N. et al. Increased thrombin-activatable fi brinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol. Endocrinol. 2008;24(9):491– 497. DOI: 10.1080/09513590802291824Zorio E., Gilabert-Estelles J., Espana F., Ramon L., Cosin R., Es tel les A. Fibrinolysis: the key to new pathogenetic mecha nisms. Curr. Med. Chem. 2008;15(9):923–929. DOI: 10.2174/092986708783955455Zorio E., Gilabert-Estelles J., Espana F., Ramon L., Cosin R., Es tel les A. Fibrinolysis: the key to new pathogenetic mecha nisms. Curr. Med. Chem. 2008;15(9):923–929. DOI: 10.2174/092986708783955455Bentov Y., Brown T.J., Akbari M.R. et al. Polymorphic variation of genes in the fi brinolytic system and the risk of ovarian cancer. PLoS One. 2009;4(6):e5918. DOI: 10.1371/journal.pone.0005918Bentov Y., Brown T.J., Akbari M.R. et al. Polymorphic variation of genes in the fi brinolytic system and the risk of ovarian cancer. PLoS One. 2009;4(6):e5918. DOI: 10.1371/journal.pone.0005918Cai Y., Jin H., Cao LQ., Gao Q., Tao J. Overexpression of TAFI promotes epithelial mesenchymal transition in endometriosis. Eur. Rev. Med. Pharmacol. Sci. 2017;21(24):5527–5533. DOI: 10.26355/EURREV_201712_13988Cai Y., Jin H., Cao LQ., Gao Q., Tao J. Overexpression of TAFI promotes epithelial mesenchymal transition in endometriosis. Eur. Rev. Med. Pharmacol. Sci. 2017;21(24):5527–5533. DOI: 10.26355/EURREV_201712_13988Neil E.K., Stewart R.J., Schneider M.M., Nesheim M.E. A functional assay for measuring activated thrombin-activatable fi brinolysis inhibitor in plasma. Anal. Biochem. 2004,330;332–341. DOI: 10.1016/j.ab.2004.04.007Neil E.K., Stewart R.J., Schneider M.M., Nesheim M.E. A functional assay for measuring activated thrombin-activatable fi brinolysis inhibitor in plasma. Anal. Biochem. 2004,330;332–341. DOI: 10.1016/j.ab.2004.04.007

The authors declare that there are no conflicts of interest present.